Quick Answer
Arbutus Biopharma Corp reported Total Revenue of $14.08 million for the year ending 2025.
- Arbutus Biopharma Corp showed an increase of +128.2% in Total Revenue from 2024 to 2025.
- This data is from Arbutus Biopharma Corp's annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $2.13 million | Q2 2013: $2.84 million | Q3 2013: $2.96 million | Q4 2013: $752.0 thousand | Q1 2014: $4.43 million | Q2 2014: $1.81 million | Q3 2014: $4.36 million | Q4 2014: $4.35 million | Q1 2015: $4.68 million | Q2 2015: $3.44 million | Q3 2015: $4.07 million | Q4 2015: $12.69 million | Q1 2016: $603.0 thousand | Q2 2016: $309.0 thousand | Q3 2016: $774.0 thousand | Q4 2016: -$195.0 thousand | Q1 2017: $235.0 thousand | Q2 2017: $1.04 million | Q3 2017: $6.89 million | Q4 2017: $2.53 million | Q1 2018: $1.44 million | Q2 2018: $1.24 million | Q3 2018: $1.59 million | Q4 2018: $1.68 million | Q1 2019: $679.0 thousand | Q2 2019: $653.0 thousand | Q3 2019: $3.06 million | Q4 2019: $1.62 million | Q1 2020: $1.49 million | Q2 2020: $1.51 million | Q3 2020: $1.52 million | Q1 2021: $2.11 million | Q2 2021: $2.33 million | Q3 2021: $3.34 million | Q1 2022: $12.58 million | Q2 2022: $14.24 million | Q3 2022: $5.95 million | Q1 2023: $6.69 million | Q2 2023: $4.65 million | Q3 2023: $4.66 million | Q1 2024: $1.53 million | Q2 2024: $1.73 million | Q3 2024: $1.34 million | Q1 2025: $1.76 million | Q2 2025: $10.74 million | Q3 2025: $529.0 thousand.
- Over the full 17 years of available data (2009 to 2025), Arbutus Biopharma Corp's Total Revenue has declined by 2.4%.
- Historical annual values: Fiscal year 2025: $14.08 million | Fiscal year 2024: $6.17 million | Fiscal year 2023: $18.14 million | Fiscal year 2022: $39.02 million | Fiscal year 2021: $10.99 million | Fiscal year 2020: $6.91 million | Fiscal year 2019: $6.01 million | Fiscal year 2018: $5.95 million | Fiscal year 2017: $10.70 million | Fiscal year 2016: $1.49 million | Fiscal year 2015: $23.28 million | Fiscal year 2014: $14.95 million | Fiscal year 2013: $15.47 million | Fiscal year 2012: $14.11 million | Fiscal year 2011: $16.81 million | Fiscal year 2010: $21.35 million | Fiscal year 2009: $14.43 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: